Belgium's UCB partners with China's Antengene

Belgian biopharmaceutical company UCB has signed a global licensing agreement with China's Antengene, driven by the increasing global demand for Chinese-developed drug candidates. This deal highlights the growing collaboration between Western and Chinese biotech firms. Key details include the licensing of UCB's drug candidates to Antengene for further development and commercialization.

Summarized from the sources above. Read the originals for the full story.